Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
cancer subtype
|
| gptkbp:approvedTherapy |
gptkb:pembrolizumab
gptkb:ipilimumab gptkb:nivolumab |
| gptkbp:associatedWith |
gptkb:Lynch_syndrome
defective DNA mismatch repair |
| gptkbp:characterizedBy |
high level of microsatellite instability
|
| gptkbp:commonIn |
gptkb:endometrial_cancer
colorectal cancer gastric cancer |
| gptkbp:diagnosedBy |
PCR-based MSI testing
immunohistochemistry for MMR proteins |
| gptkbp:frequency |
~10% of gastric cancers
~15% of colorectal cancers ~20-30% of endometrial cancers |
| gptkbp:fullName |
gptkb:microsatellite_instability-high_cancer
|
| gptkbp:hasBiomarker |
MSI-H status
|
| gptkbp:hasGeneticAlteration |
MLH1 mutation
MSH2 mutation EPCAM deletion MSH6 mutation PMS2 mutation |
| gptkbp:hasSubgroup |
microsatellite instability cancers
|
| https://www.w3.org/2000/01/rdf-schema#label |
MSI-H cancer
|
| gptkbp:predicts |
immune checkpoint inhibitors
|
| gptkbp:prognosis |
generally better prognosis in colorectal cancer
|
| gptkbp:significance |
may indicate hereditary cancer risk
predicts benefit from immunotherapy |
| gptkbp:bfsParent |
gptkb:microsatellite_instability-high_cancer
|
| gptkbp:bfsLayer |
6
|